Model-Based Approach for Designing an Efficient Bioequivalence Study for Highly Variable Drugs
The statistical procedures as outlined by the European Medicines Agency (EMA) and United States Food and Drug Administration (FDA) guidelines for bioequivalence testing of highly variable drugs (HVDs) are complex. Additionally, the sample size is affected by clinical study designs or practical real-...
Guardado en:
Autores principales: | Eunjung Song, Woojoo Lee, Bo-Hyung Kim |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/686337b3d33f4425bb72ad40e19399df |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
INFLUENCE OF SEX DIFFERENCES ON PHARMACOKINETICS OF DRUGS WITHIN THE FRAMEWORK OF BIOEQUIVALENCE STUDIES OF GENERIC MEDICINAL PRODUCTS
por: D. P. Romodanovsky, et al.
Publicado: (2018) -
Concept and utility of population pharmacokinetic and pharmacokinetic/pharmacodynamic models in drug development and clinical practice
por: Roganović Maša, et al.
Publicado: (2021) -
Infliximab Efficacy May Be Linked to Full TNF-α Blockade in Peripheral Compartment—A Double Central-Peripheral Target-Mediated Drug Disposition (TMDD) Model
por: David Ternant, et al.
Publicado: (2021) -
Variability of Tacrolimus Trough Concentration in Liver Transplant Patients: Which Role of Inflammation?
por: Anaelle Chavant, et al.
Publicado: (2021) -
Antiviral and antiretroviral drug shortages amidst COVID-19: How Africa is struggling
por: Sudhan Rackimuthu, et al.
Publicado: (2021)